BD Diagnostics- Infectious Disease products have been developed to help improve patient outcomes by delivering cost-effective, rapid molecular and chromogenic testing solutions intended to aid in the prevention and control of healthcare-associated infections (HAIs). Our products provide laboratories with the capability to deliver critical, relevant information in a timeframe that enables significantly earlier clinical decisions.
Our current portfolio includes assays for Group B Streptococcus (GBS), methicillin-resistant Staphylococcus aureus (MRSA), C. difficile toxin B gene (tcdB), and a combination assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (MRSA and SA).
News & Events
- First Partner Assay on the BD MAX™ System Launches in Europe
- BD and Lab21 Collaborate to Develop New Oncology Assays on the BD MAX™ Platform
- New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
- New, Fully Automated BD MAX™ MRSA Assay Rapidly Identifies Patients Colonized with Deadly Superbug
- BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System
- BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System
- BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases
- BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System
- BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians
- BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System
- BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay
- BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus
- BD Completes Acquisition of HandyLab, Inc.
- BD Adds Surveillance Capability to Infectious Disease Portfolio
- BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
- BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
Learn More About...
-
Healthcare-Associated Infections At A Glance (PDF)
-
BD LabO™ Spring 2010 issue features the BD GeneOhm™ Cdiff Assay (PDF)
-
BD GeneOhm™ Cdiff Assay Backgrounder (PDF)
-
BD Geneohm™ MRSA Assay At A Glance (PDF)
-
Benefits of Rapid Testing (PDF)
-
Key Research Papers Relevant to the BD GeneOhm™ MRSA Assay (PDF)
-
BD LabO™ Winter 2007 issue features HAIs (PDF)